There is something to be said about being open to taking risks - to being vulnerable. It’s a valuable lesson that each story in the podcast episode brings to light in different ways. SEGMENT 1: Nemour’s performance improvement manager Jessica Jordan has a theater background and a passion for community service. Her philosophy of continuous improvement can be summed up on one word: vulnerability - an idea carried forward into healthcare from her days doing improv. SEGMENT 2: In May 2019, the U.S. Food and Drug Administration approved a gene therapy for the treatment of spinal muscular atrophy - a devastating and often deadly neuromuscular disease. In fact,  Nemours was part of the successful clinical trial that led to FDA approval for wider use of this $2 million dollar therapy. It didn’t take long for Nemours to be approached about the possibility of administering the drug to its first SMA patient outside of the clinical trial. But there were challenges: It’s a new treatment. The patient was from outside the U.S.,  and time was short. Not to be deterred,  Nemours pediatrics neurologist Dr. Richard Finkel, and Clinical Research Coordinator Julia Balashkina led a team from across the enterprise to help get a little girl the therapy she so desperately needed. SEGMENT 3: Pediatric anesthesiologist Dr. Katari Carello is devoted to the kids she serves. Yet soon after arriving at Nemours with her physician-husband and their young child, she learned she was pregnant again - with twins. New job? Pregnant with twins? No problem, said her colleagues- just one of many ways she felt welcomed and supported as a member of the Nemours family.